Mylan's Advair generic starts at one-third price

Feb 12, 2019

Mylan has announced that its generic version of GlaxoSmithKline’s asthma treatment Advair, Wixela Inhub, is priced 70 percent lower than the blockbuster. The drugmaker received approval for the generic from the U.S. Food and Drug Administration in January.

The med is the first generic of Advair and is approved in three doses. It is priced between $93.71 and $153.14.

"We've had numerous discussions with customers about the need for a unique launch strategy for the first substitutable generic of Advair Diskus that increases affordability to all in our healthcare system," said Mylan's chief commercial officer Tony Mauro. "We trust that by launching Wixela Inhub at a significantly discounted list price, we will demonstrate the savings that generics can deliver for patients through reduced out-of-pocket costs, as well as the U.S. healthcare system overall."

Wixela Inhub is indicated for the twice daily treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta agonists; maintenance treatment of COPD; and the reduction of COPD exacerbations in patients with a history of exacerbations.

Read the full release

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!